垠艺TM支架与PARTNER支架治疗急性心肌梗死的安全性比较

摘要

目的:探讨垠艺TM微肓孔载药支架在急性心肌梗死(AMI)经皮冠状动脉介入(PCI)治疗中应用的安全性.方法:选拟行PCI治疗的AMI患者190例,并按植入支架类型分为垠艺TM微盲孔载药支架组(A组,100例)和国产雷帕霉素洗脱支架(PARTNER)组(B组,90例),对2组患者住院期间、术后30 d及术后6个月的主要心血管不良事件(MACE)和支架内血栓的发生情况进行随访和对比分析.结果:住院期间A组无急性、亚急性及晚期血栓发生,B组发生1例亚急性支架内血栓.住院期间、术后30d及6个月时2组MACE的发生率差异均无统计学意义(P＞0.05).结论:垠艺TM微盲孔载药支架在治疗AMI中与PARTNER支架一样有较好的安全性.%Objective: To investigate the safety of Yinyi micropole drug coated stent in percutaneous coronary intervention (PCI) in patients with acute myocardial infarction(AMI). Methods:One hundred and ninety consecutive patients with AMI underwent PCI were divided into Yinyi micropole drug coated stent group (Group A, n= 100) and domestic produced rapamycin-eluting stent (PARTNER) group (Group B,n= 90)according to the type of the stents. The incidence of major adverse cardiovascular event (MACE) and stent thrombosis was evaluated during in-hospital, 30 days and 6 months follow up after PCI in patients of two groups. Results: There was no acute, subacute and late in-stent thrombosis during the hospital stay in group A, but one case stent thrombosis in group B (P ＞ 0.05). There were no significant differences in rates of MACE during the hospital stay, 30 days and 6 months after operation between the 2 groups(P ＞ 0.05). Conclusion: Implantation of Yinyi micropole drug coated stent after PCI is as safe as PARTNER stent in patients with AMI.